Lundbeck
HLUN-B.CO
#2868
Rank
NZ$9.68 B
Marketcap
NZ$10.21
Share price
-9.04%
Change (1 day)
-2.50%
Change (1 year)
Lundbeck is a Danish pharmaceutical company that produces various pharmaceutical products and has the indications schizophrenia, depression, Parkinson's disease and sleep disorders.

Earnings for Lundbeck (HLUN-B.CO)

Earnings in 2025 (TTM): NZ$1.46 Billion

According to Lundbeck's latest financial reports the company's current earnings are NZ$3.61 Billion. In 2024 the company made an earning of NZ$0.92 Billion, an increase over its 2023 earnings that were of NZ$0.73 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Lundbeck from 2009 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) NZ$1.46 B59.44%
2024 NZ$0.92 B25.74%
2023 NZ$0.73 B21.77%
2022 NZ$0.60 B31.57%
2021 NZ$0.45 B-4.61%
2020 NZ$0.47 B-45.06%
2019 NZ$0.87 B-34.04%
2018 NZ$1.32 B12.83%
2017 NZ$1.17 B93.99%
2016 NZ$0.60 B-137.28%
2015 -NZ$1.62 Billion-1246.24%
2014 NZ$0.14 B-72.36%
2013 NZ$0.51 B4.38%
2012 NZ$0.48 B-55.18%
2011 NZ$1.09 B5.65%
2010 NZ$1.03 B-5.9%
2009 NZ$1.09 B